The Prostate Cancer Foundation Appoints Two New Board Members
SANTA MONICA, Calif., April 5 /PRNewswire/ -- The Prostate Cancer Foundation has announced the addition of two new members to its Board of Directors: Ambassador Earle I. Mack, senior partner of The Mack Company, and Henry L. Nordhoff, chairman, president and chief executive officer of Gen-Probe Incorporated. Mack rejoined the Board following his service as the United States Ambassador to Finland.
"The Prostate Cancer Foundation is adding valuable new expertise to our Board with the inclusion of Earle Mack and Henry Nordhoff," said Leslie D. Michelson, chief executive officer of the Prostate Cancer Foundation. "Each member brings a unique perspective to our mission of finding better treatments and a cure for prostate cancer, and we look forward to benefiting from their considerable expertise."
About Earle Mack
Ambassador Earle Mack has a long history associated with business, the arts, philanthropy, public service and education. Before he was sworn-in as Ambassador to Finland in May 2004, he was senior partner of The Mack Company, a real estate firm established a century ago. In addition, he was a board member of Mack-Cali Realty Corporation (NYSE) and served on the executive committee of the National Realty Council.
Dedicated to the arts, Ambassador Mack is chairman emeritus of the New York State Council on the Arts and previously served as its chairman and chief executive officer from 1996-1999. He is a former board member of the New York City Ballet and a former co-chairman of the board of the Dance Theater of Harlem. Ambassador Mack is a former member of the New York Governor's Committee on Scholastic Achievement, a former member of the advisory board for the New York State Business Venture Partnership, and chairman of the New York State Racing Commission for seven years.
Ambassador Mack received his Bachelor of Science degree from Drexel University and attended Fordham School of Law. He served as second lieutenant in the U.S. Army Infantry, active duty, and first lieutenant in the U.S. Army Infantry and Military Police, reserve duty. He is married and has two children.
About Henry Nordhoff
Henry Nordhoff is a well-known leader in the biotech industry. He joined Gen-Probe Incorporated in July 1994 as president and chief executive officer. Following the spin-off from Chugai Pharmaceutical Co., Ltd. in September 2002, he was also appointed chairman of its board of directors. Prior to joining Gen-Probe, Nordhoff served as president and chief executive officer of TargeTech, Inc., a gene therapy company focused on the potential treatment of inherited diseases which merged with Immune Response Corporation in 1992. Previously, Nordhoff spent over 16 years at Pfizer Inc., holding several senior positions in Brussels, Seoul, Tokyo and New York.
Nordhoff serves as a member of the board of directors of AdvaMed, Washington, D.C.; BIOCOM, San Diego, CA; Molecular Light Technology, Cardiff, Wales; and MannKind Corporation, Valencia, CA. He is currently chairman of the San Diego Regional Economic Development Corporation and incoming chairman of the California Healthcare Institute. He serves on the advisory boards of the Cancer Center, the Rady School of Management, and the Jacob School of Engineering, all at the University of California, San Diego. He is a member of the board of trustees of the University of San Diego. Nordhoff received a Bachelor of Arts degree in international relations and political economy from The Johns Hopkins University and a Master of Business Administration degree in international business and finance from Columbia University.
Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests that are used primarily to diagnose human diseases and screen donated human blood.
About the Prostate Cancer Foundation
The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for prostate cancer research. Founded in 1993, the PCF has raised more than $260 million and provided funding for prostate cancer research to more than 1,200 researchers at 100 institutions worldwide. The PCF has a simple, yet urgent goal: to find better treatments and a cure for recurrent prostate cancer. For more information, please visit http://www.prostatecancerfoundation.org.
Contacts: Sarah Evans (310) 570-4705 email@example.com Katie Lambe (310) 570-4713 firstname.lastname@example.orgThe Prostate Cancer Foundation
CONTACT: Sarah Evans, +1-310-570-4705,email@example.com, or Katie Lambe, +1-310-570-4713,firstname.lastname@example.org
Web site: http://www.prostatecancerfoundation.org/